Copy to clipboard 
Results from a clinical trial evaluating i-FACTOR® Peptide Enhanced Bone Graft in non-instrumented lumbar fusion demonstrate that elderly patients treated with i-FACTOR bone graft plus local bone had a statistically significantly higher fusion rate vs. those treated with allograft plus local bone.
“In Scandinavia, surgeons often consider performing non-instrumented fusion when there is instability in elderly patients, but allograft bone has notoriously low fusion rates in this population,” said Dr. Michael Kjær Jacobsen, principal investigator. “i-FACTOR shows an increased fusion rate versus allograft.”
The double-blind, prospective, randomized study involved more than 100 degenerative spondylolisthesis patients, 60 years or older, in Denmark. Participants underwent decompression and non-instrumented posterolateral fusion, randomized to either i-FACTOR bone graft or fresh frozen allograft bone, both mixed with local bone graft.
Recipients of i-FACTOR showed a 50% fusion rate vs. 20% in the allograft group at one year. Patient-reported outcomes at baseline and follow-up were similar between the groups. Longer term follow-up to evaluate the maintenance of clinical outcomes is in process.
“This study is a valuable addition to our clinical evidence base,” said Glen Kashuba, Chief Executive Officer of Cerapedics. “This is now our fourth prospective clinical study in which i-FACTOR Bone Graft has demonstrated a clear clinical benefit and builds upon our previously reported fusion in various spine applications.”
Cerapedics launched i‑FACTOR in 2016. The drug/device combination is based on synthetic small peptide technology that accelerates new bone formation. It is in a new category of bone graft technology and is one of only two drug/device combination products approved by FDA, joining Medtronic’s Infuse.
Results from a clinical trial evaluating i-FACTOR® Peptide Enhanced Bone Graft in non-instrumented lumbar fusion demonstrate that elderly patients treated with i-FACTOR bone graft plus local bone had a statistically significantly higher fusion rate vs. those treated with allograft plus local bone.
“In Scandinavia, surgeons often consider...
Results from a clinical trial evaluating i-FACTOR® Peptide Enhanced Bone Graft in non-instrumented lumbar fusion demonstrate that elderly patients treated with i-FACTOR bone graft plus local bone had a statistically significantly higher fusion rate vs. those treated with allograft plus local bone.
“In Scandinavia, surgeons often consider performing non-instrumented fusion when there is instability in elderly patients, but allograft bone has notoriously low fusion rates in this population,” said Dr. Michael Kjær Jacobsen, principal investigator. “i-FACTOR shows an increased fusion rate versus allograft.”
The double-blind, prospective, randomized study involved more than 100 degenerative spondylolisthesis patients, 60 years or older, in Denmark. Participants underwent decompression and non-instrumented posterolateral fusion, randomized to either i-FACTOR bone graft or fresh frozen allograft bone, both mixed with local bone graft.
Recipients of i-FACTOR showed a 50% fusion rate vs. 20% in the allograft group at one year. Patient-reported outcomes at baseline and follow-up were similar between the groups. Longer term follow-up to evaluate the maintenance of clinical outcomes is in process.
“This study is a valuable addition to our clinical evidence base,” said Glen Kashuba, Chief Executive Officer of Cerapedics. “This is now our fourth prospective clinical study in which i-FACTOR Bone Graft has demonstrated a clear clinical benefit and builds upon our previously reported fusion in various spine applications.”
Cerapedics launched i‑FACTOR in 2016. The drug/device combination is based on synthetic small peptide technology that accelerates new bone formation. It is in a new category of bone graft technology and is one of only two drug/device combination products approved by FDA, joining Medtronic’s Infuse.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
